Fibroblast growth factor 1 levels are elevated in newly diagnosed type 2 diabetes compared to normal glucose tolerance controls

Wang

Exp Clin Endocrinol Diabetes

et al. 2017

As a transducer of PPARγ signaling, recent evidence supports that fibroblast growth factor 1 (FGF1) mediates adipose tissue remodeling and insulin sensitivity. This study is to assess the role of serum FGF1 in obesity. A hospital-based case-control study of 154 subjects was conducted. Serum level of FGF1 was measured by enzyme-linked immunosorbent assay. The serum level of FGF1 in the lean (119.0 [103.1-146.1] pg/ml) was higher than it in the subjects with overweight/obesity (111.9 [80.3-127.4] pg/ml, P=0.009). Binary logistic regression models found a reverse association between serum FGF1 level and the risk of overweight/obesity (adjusted odds ratio=0.990, 95% confidence interval [0.981-0.998], P=0.019). Furthermore, serum FGF1 reversely correlated with body mass index (r=-0.176, P=0.029), systolic blood pressure (r=-0.224, P=0.005), diastolic blood pressure (r=-0.185, P=0.022) and triglycerides (r=-0.162, P=0.044). Multiple stepwise linear regression analysis found serum level of FGF1 was dependent on anti-diabetic drugs, hemoglobin A1C, body mass index and sex. Serum level of FGF1 is associated with the decreased risk of obesity in human.

Section: Adjustmentsupporting

confidence: 61%

Section: Discussionmentioning

confidence: 99%

Section: Adjustmentmentioning

confidence: 99%

See 1 more Smart Citation

Serum Fibroblast Growth Factor 1 is Associated with the Decreased Risk of Obesity in Human

Wang

Exp Clin Endocrinol Diabetes

et al. 2017

“…Exogenous FGF1 can improve metabolic disorders in rodents through endocrine manner ( 5 ). In adults, circulating FGF1 levels are reported to be significantly reduced in obese individuals ( 7 ), but significantly increased in T2DM patients ( 8 ). Serum FGF1 levels were positively correlated with BMI, waist circumference (WC), fasting glucose and hemoglobin A1c (HbA1c) in T2DM adults ( 8 ).…”

Section: Introductionmentioning

confidence: 99%

“…In adults, circulating FGF1 levels are reported to be significantly reduced in obese individuals ( 7 ), but significantly increased in T2DM patients ( 8 ). Serum FGF1 levels were positively correlated with BMI, waist circumference (WC), fasting glucose and hemoglobin A1c (HbA1c) in T2DM adults ( 8 ). The correlation between FGF1 and other glucose/lipid metabolic variables following weight loss in obese individuals remains unknown.…”

Section: Introductionmentioning

confidence: 99%

Characterization of fibroblast growth factor 1 in obese children and adolescents

Wang

Yan

Cai

et al. 2018

Endocrine Connections

BackgroundFibroblast growth factor 1 (FGF1) can regulate glucose and lipid metabolism in obese mice. Serum FGF1 has increased in type 2 diabetes mellitus adults and correlated with BMI. This study aimed to indicate conventional weight loss effects on FGF1 in obese children and adolescents.Materials and methodsClinical and metabolic parameters of 88 lean and obese individuals (ages 5–15 years) and 39 obese individuals followed with 6 months of lifestyle intervention were collected. Serum FGF1 levels were detected through enzyme-linked immunosorbent assays.ResultsFGF1 levels were increased in obese individuals. Serum FGF1 levels were significantly correlated with BMI and waist circumferences (r = 0.377, P = 0.012; r = 0.301, P = 0.047, respectively). Multivariate stepwise linear regression analyses showed that FGF1 levels were significantly correlated with HbA1c and HOMA-IR (β = 0.371, P = 0.008; β = 0.323, P = 0.021, respectively). Weight loss (2.3 ± 0.1 kg) was accompanied by a significant reduction of circulating FGF1 levels (7.2 ± 0.4 pg/mL). Changes in FGF1 were significantly correlated with changes in fasting glucose, HOMA-IR and low-density lipoprotein cholesterol (β = 0.277, P = 0.020; β = 0.474, P < 0.001; β = 0.320, P = 0.008, respectively).ConclusionFGF1 was related to increased risk of insulin resistance in obese children and adolescents. Serum FGF1 reduced after weight loss in obese individuals and was associated with the improvement of insulin resistance. Changes in serum FGF1 were more correlated with insulin resistance than changes in obesity per se.

WIREs Mechanisms of Disease

New developments in the biology of fibroblast growth factors

Ornitz

Itoh

2022

The fibroblast growth factor (FGF) family is composed of 18 secreted signaling proteins consisting of canonical FGFs and endocrine FGFs that activate four receptor tyrosine kinases (FGFRs 1-4) and four intracellular proteins (intracellular FGFs or iFGFs) that primarily function to regulate the activity of voltagegated sodium channels and other molecules. The canonical FGFs, endocrine FGFs, and iFGFs have been reviewed extensively by us and others. In this review, we briefly summarize past reviews and then focus on new developments in the FGF field since our last review in 2015. Some of the highlights in the past 6 years include the use of optogenetic tools, viral vectors, and inducible transgenes to experimentally modulate FGF signaling, the clinical use of small molecule FGFR inhibitors, an expanded understanding of endocrine FGF signaling, functions for FGF signaling in stem cell pluripotency and differentiation, roles for FGF signaling in tissue homeostasis and regeneration, a continuing elaboration of mechanisms of FGF signaling in development, and an expanding appreciation of roles for FGF signaling in neuropsychiatric diseases.